Alterations of the recently cloned fragile histidine triad (FHIT) gene at chromosome 3p14.2 are frequent in a variety of solid tumours and cancer cell lines. Based on these ®ndings, FHIT has been proposed as a putative tumour-suppressor gene. We evaluated the mRNA expression of the FHIT gene in samples from 55 patients with various haematological malignancies (21 AML, 8 CML, 10 CLL, seven low-grade and nine highgrade Non-Hodgkin's lymphomas), in a panel of 16 leukaemia cell lines, in normal mature haematopoietic cells of both myeloid and lymphoid lineage, as well as in CD34
Introduction
Chromosome 3p often shows deletions and translocations in human cancer, particularly in carcinomas of the breast, lung, head and neck and kidney Kastury et al., 1996; Mitelman et al., 1997; Zbar et al., 1987) . Chromosome and DNA transfer of dierent chromosome 3p regions were shown to suppress the tumour phenotype of cancer cell lines (Killary et al., 1992; Sanchez et al., 1994) . Based on these observations the short arm of chromosome 3 is a candidate region for the presence of tumour-suppressor genes. Recently, the fragile histidine triad (FHIT) gene was identi®ed at the chromosomal region 3p14.2 encompassing the most common inducible human fragile site FRA3B Ong et al., 1997; Rassool et al., 1996; Zimonjic et al., 1997) . Fragile sites are chromosomal regions prone to genetic instability, chromosomal breakage and structural rearrangements and thus their disruption could contribute to carcinogenesis (LeBeau and Rowley, 1984; Yunis and Soreng, 1984) . The FHIT gene consists of 10 exons dispersed over about 1 Mb and encodes a 1.1 kb mRNA. The open reading frame spans exon 5 to exon 9, and translation results in a small 16.8 kDa protein with diadenosine triphosphate hydrolase activity possibly involved in nucleotide metabolism (Barnes et al., 1996; Lima et al., 1997) . Genomic alterations of the FHIT gene in tumours include loss of heterozygosity identi®ed by polymorphic DNA markers, deletions of both alleles as well as insertion of various small DNA sequences between and within the gene's exons. Aberrant transcripts of various sizes are frequent in solid tumours, but may also be seen in normal nonneoplastic tissues which do not exhibit alterations of the FHIT gene Negrini et al., 1996; Ohta et al., 1996; Sozzi et al., 1996) . Possible genetic mechanisms giving rise to these fragments include abnormalities of RNA splicing and processing as well as exonic deletions. The extent to which aberrant transcripts are translated into FHIT protein in human tumours is unclear at present Otterson et al., 1998; Sozzi et al., 1997) .
In contrast to solid tumours haematological neoplasms have been less extensively characterized with respect to alterations of the FHIT gene and its mRNA and protein expression. Aberrant FHIT mRNA transcripts were reported in chronic myelogenous leukaemia (CML) (Carapeti et al., 1996; Sugimoto et al., 1997) , acute myelogenous leukaemia (AML) (Carapeti et al., 1996; Lin et al., 1997; Sugimoto et al., 1997) , acute lymphocytic leukaemia (Sugimoto et al., 1997) and chronic lymphocytic leukaemia (CLL) (Gayther et al., 1997; Sugimoto et al., 1997) . However, a systematic survey of various haematological neoplasms with respect to FHIT mRNA and protein expression patterns and a comparison with their respective normal cellular counterparts has not been reported. We therefore investigated FHIT mRNA and protein expression in a panel of leukaemia and lymphoma cell lines and in clinical samples of leukaemias and lymphomas. For comparison we analysed mature normal haematopoietic cells of both myeloid and lymphoid lineage as well as CD34
Results

FHIT mRNA expression and gene structure in normal haematopoietic cells
We investigated FHIT mRNA expression in ®ve granulocyte, in ®ve monocyte and in eight lymphocyte samples from peripheral blood of healthy blood donors, as well as in four specimens of CD34 + haematopoietic progenitor cells. The 702-bp wild-type FHIT transcript was present in all samples (Figure 1 ). PCR products derived from this transcript invariably gave a stronger signal than aberrant transcripts. All wt 702-bp PCR products sequenced corresponded to the normal FHIT gene sequence. Overall we detected 23 abnormally sized dierent FHIT mRNA transcripts (Figure 2 ). At least one abnormally-sized transcript was seen in three granulocyte, three monocyte, seven lymphocyte and in all four CD34 + progenitor cell samples. Only six of these aberrant transcripts had been detected on visual inspection of ethidium bromide-stained agarose gels prior to Southern blotting of PCR products. Seven samples showed one aberrant transcript only, but in ten samples multiple smaller-and larger-than-wt transcripts were seen. The most frequent aberrant transcript of about 780 bp was seen in 3/10 myeloid, 5/8 lymphoid and in all four CD34 + progenitor cell specimens. This PCR product was isolated from agarose gels of three separate samples (normal lymphocytes, but also one CLL and one high-grade NHL), and sequenced. It revealed dierent transcripts of 771 bp or 774 bp. Nine dierent abnormally-sized transcripts ranging from 230 ± 851 bp in length derived from normal monoand lymphocytes were sequenced. A splice variant lacking the ®rst 11 bases of exon 10 in the 3' untranslated region (691-bp transcript) was detected in three samples (Mao et al., 1996) . The most frequent aberrant fragments ranged from 742 ± 774 bp and revealed DNA insertions of 40 ± 72 bp between exons 4 and 5. A previously described 72-bp insertion shared a 76% homology to the Notch 4 gene (Hayashi et al., 1997) . In a normal monocyte sample we found a novel 53-bp insertion between exon 8 and 9 localized inframe within the open reading frame of the FHIT coding region. The inserted sequence was nonrepetitive and unrelated to the FHIT gene or any other gene sequence deposited in the EMBL data base. Other novel insertions of 40-, 47-and 149-bp, located outside the FHIT open reading frame, were seen in one monocyte and one lymphocyte sample. We did not ®nd larger bands created through heteroduplex formation as previously reported Michael et al., 1997) . Shorter FHIT transcripts resulted from loss of entire exons generating splice junctions between unrelated exons: exons 3 and 9 (230-bp transcript), exons 3 and 8 (310-bp), exons 4 and 8 (394-bp) and exons 7 and 9 (623-bp). The latter transcript was identical to an exon 8 deletion variant observed in normal lung and breast tissue Fong et al., 1997) . Assessment of genomic DNA by Southern blotting showed no FHIT gene alterations in any normal haematopoietic cells including those samples displaying aberrant FHIT mRNA transcripts.
FHIT protein analysis in normal haematopoietic cells
The 16.8 kDa FHIT protein was detected by Western blot analysis in all normal mature haematopoietic cells of both myeloid and lymphoid lineage (three granulo- 
FHIT mRNA expression and gene structure in haematological malignancies
The 702-bp wt transcript was present in 15/16 leukaemia cell lines (94%) and in 48/55 patients (87%). All 702-bp FHIT transcripts sequenced corresponded to the expected wt sequence without any mutations. No FHIT message was detected in the cell line Nalm6 and in fresh samples from one AML, four Lg-NHL and two Hg-NHL. Overall we detected 33 dierent abnormally sized FHIT transcripts ranging from 240 ± 1700 bp. Such aberrant FHIT mRNA transcripts consisting of both smaller-and/or largerthan-wt sizes were seen in 14/16 leukaemia cell lines (nine myeloid, ®ve lymphoid), 18/21 AML, 7/8 CML, 9/10 CLL, 2/7 Lg-NHL, as well as in 7/9 Hg-NHL. The vast majority of cases harboured more than one aberrant transcript (range 1 ± 9). All types of aberrant FHIT transcripts were seen in conjunction with the wt 702-bp product. Except for two myeloid cell lines (K562 and U937) the band intensity of the wt fragment was always stronger than or equal to aberrant transcripts. As in normal cells the 780-bp mRNA fragment was most frequent (38/55 cases). In three cases (K562, Hg-NHL 5, Hg-NHL 9) we found the same splice variant of exon 10 seen in normal haematopoietic cells. Sequencing of aberrant transcripts revealed a broad variety of FHIT cDNA deletions or splice variants as well as DNA sequence insertions and combinations of both ( Figure 2 ). Smaller-than-wt transcripts were due to exon deletions (241-bp, 394-bp, 634-bp transcripts) or contained small DNA insertions replacing FHIT exons (464-bp, 476-bp, 547-bp and 558-bp transcripts). The 547-and 558-bp transcripts resulted from use of a cryptic splice site 103 bp within intron 5. Larger-than-wt cDNAs contained insertions of dierent size and origin adjacent to exons 3, 4, 5 and 7. The same 72-bp insertion seen in one of our lymphocyte samples was also detected in a CLL and a high-grade NHL.
Southern blotting of genomic DNA did not reveal any abnormal restriction fragments in neoplasms with abnormal FHIT mRNA expression and/or with undetectable FHIT message (one cell line, one AML, two Hg-NHL, three Lg-NHL) suggesting an intact FHIT gene locus. As an exception, DNA from the myeloid leukaemic cell lines K562 and U937 showed marked reduction of the intensity or virtual absence of restriction fragments. This points to the presence of large deletions including most exons. XbaI digests revealed an extra 9.4 kb fragment in two normal and two leukaemia samples suggesting the presence of a pseudogene .
FHIT protein analysis in haematological malignancies
We studied FHIT protein expression in six myeloid cell lines (K562, U937, NB4, MV4-11, KG1, HL60), three lymphoid cell lines (Raji, CEM, Nalm6) and fresh samples from six AML, one CML and two CLL patients (Figure 3 ). However, no protein extracts suitable for Western blotting were available from the lymphomas. The FHIT protein of the expected size was only present in neoplasms expressing the wt 702-bp transcript. It was detected in 4/6 myeloid and 2/3 lymphoid cell lines, as well as in 4/6 AML, in the CML and in both CLL samples. However, FHIT protein expression was very weak in one myeloid leukaemia cell line (MV4-11), one CML and two AML cases. Three cell lines (K562, U937, Nalm6) and one AML patient did not express any detectable FHIT protein.
We did not observe any abnormally-sized FHIT protein bands with the antibody used.
Discussion
Since the FHIT gene is usually expressed at very low levels , we used a sensitive yet highly speci®c nested touchdown RT-PCR technique to screen both normal and malignant haematopoietic cells for aberrant FHIT mRNA expression patterns. Southern blot hybridization of ampli®cation products with a fulllength FHIT cDNA probe permitted us in most of our samples to trace additional FHIT transcripts which had escaped detection on inspection of agarose gels.
Since Southern blot hybridization of PCR products has only rarely been performed in a systematic way, we conclude that the frequency of aberrant transcripts of the FHIT gene is underreported in the current literature (Michael et al., 1997; Panagopoulos et al., 1997; Wang et al., 1998) . We show that aberrant FHIT mRNA expression is frequent in dierent types of haematological neoplasms as reported for many types of solid tumours. The majority of aberrant transcripts seen in our series of leukaemias and lymphomas were previously described in various carcinomas Negrini et al., 1996; Ohta et al., 1996; Sozzi et al., 1996) . This may point to a common mechanism of disturbed gene transcription operative in both groups of malignancies. In addition, we found several novel types of aberrant transcripts resulting from the insertion of short unique DNA sequences between dierent exons. The mechanisms responsible for the generation of aberrant FHIT transcripts are not yet fully elucidated. Our cDNA sequencing data would support the notion that aberrant or alternative splicing is a prime mechanism of generating aberrant FHIT transcripts in haematological neoplasia, as reported for the candidate tumour suppressor gene TSG101 in normal lymphocytes, CLL, melanoma, gynaecological tumours and lung cancer (Gayther et al., 1997; Lee and Feinberg, 1997) . Interestingly, aberrant transcripts were also described in non-malignant tissues including human lung, liver, peripheral blood lymphocytes and other cell types Fong et al., 1997; Gayther et al., 1997; Panagopoulos et al., 1997; van den Berg et al., 1997) . We now con®rm and extend these ®ndings in our survey of various types of normal haematopoietic cells which frequently showed both smaller-and largerthan-wt transcripts. These aberrant transcripts in normal cells most likely resulted from aberrant splicing and/or small DNA insertions similar to their malignant counterparts. Thus aberrant FHIT mRNA transcripts are not tumor-speci®c and may be observed both in normal and neoplastic cells.
Aberrant FHIT mRNA processing or lack of FHIT gene expression in a cell might point to altered FHIT protein expression Greenspan et al., 1997; Sozzi et al., 1997) . In contrast to data from solid tumours we never detected truncated FHIT protein in normal or neoplastic haematopoietic cells with the antibody used in our survey (Yeung et al., 1997) . This observation is corroborated by our detailed analysis of sequenced aberrant FHIT transcripts.
Disturbances of the open reading frame precluding translation were identi®ed in about one half of all aberrant transcripts seen in our samples. In about one half of aberrant transcript types with a maintained open reading frame, translation (if performed at all) would produce abnormally-sized proteins of uncertain stability. Our sequencing data would thus explain the absence of truncated proteins in the majority of cells with aberrant transcripts identi®ed in our series. We did, however, note interesting dierences in the expression of wild-type FHIT protein between normal and neoplastic haematopoietic cells. In all normal haematopoietic cell types FHIT protein was readily detected. However, we now report the novel ®nding that some haematological neoplasms mostly of myeloid lineage lacked both wt FHIT mRNA and FHIT protein. Absence or very low expression of FHIT protein may clearly distinguish some leukaemic from normal haematopoietic cells and suppression of FHIT protein production might contribute to leukaemogenesis.
The question of whether the FHIT gene acts as a classical tumour-suppressor is still controversial (Le Beau et al., 1998; Mao, 1998) . Some data argue against this notion: (a) at the genomic level point mutations possibly inactivating one allele appear to be extremely rare Gemma et al., 1997; Thiagalingam et al., 1996) ; (b) aberrant mRNA transcripts are mostly accompanied by an often predominant wt mRNA fragment, and abnormal FHIT mRNA transcripts are also found in various normal tissues (Gayther et al., 1997; Panagopoulos et al., 1997; van den Berg et al., 1997; Wang et al., 1998) ; (c) aberrant transcripts are not consistently translated into truncated protein; and (d) replacement of FHIT protein in human carcinoma cells does not always suppress tumour cell growth implying that FHIT is perhaps involved in tumorigenesis along pathways distinct from the classical tumour suppressor mechanism (Otterson et al., 1998) . On the other hand some data suggest that the wt FHIT gene product might exert tumour-suppressing activity: (a) in contrast to normal cells which invariably express normal FHIT protein, the protein may be absent in solid tumours Greenspan et al., 1997; Sozzi et al., 1997) . We now show that in contrast to normal haematopoietic cells some haematological cancers lack FHIT protein; (b) introduction of the FHIT gene into several FHIT-negative tumour cell lines may result in their loss of tumorigenicity in nude mice ; and (c) recent evidence suggests that cancerspeci®c FHIT deletions may originate through breaks and recombinations within the FRA3B fragile site Michael et al., 1997; Ong et al., 1997; Zimonjic et al., 1997) . At present, the precise role of FHIT in tumorigenesis is thus not ®rmly clari®ed. Based on our results and those of others we nevertheless believe that FHIT gene disruptions and particularly lack of FHIT protein expression may be relevant to tumorigenesis including the biology of leukaemia development. Further studies, particularly FHIT gene knock-out experiments will be of great interest to advance our understanding of the contribution of this interesting gene to cancer.
Materials and methods
Normal cells, leukaemic cell lines and clinical tumour samples
Normal haematopoietic cells were isolated from peripheral blood of healthy blood donors. Granulocytes and mononuclear cells were separated by Lymphoprep gradient centrifugation (Nycomed Pharma AS, Oslo, Norway), and subsequently monocytes and lymphocytes were isolated from the mononuclear cell fraction by Percoll gradients (Pharmacia Biotech AB, Uppsala, Sweden) (Uguccioni et al., 1996) . CD34 + progenitor cells were obtained from patients with lymphoid neoplasms in remission who were candidates for high dose chemotherapy consolidation and reinfusion of peripheral blood stem cells. Cells were mobilized using chemotherapy and granulocyte-colony-stimulating factor and harvested through leukapheresis. Apheresis products were labelled with a biotinylated anti-CD34 monoclonal antibody (CellPro, Wezembeek-Oppen, Belgium) and tagged cells were separated with a CEPRATE SC Cell Concentrater (CellPro, Wezembeek-Oppen, Belgium). The purity of the CD34 + population obtained was 490% as assessed by immunocytochemical analysis of cytospin preparations.
The panel of cell lines studied included 10 myeloid (HEL, HL60, U937, K562, KG1, Kasumi, EM3, THP1, NB4, MV4-11) and six lymphoid (CEM, Jurkat, Molt4, Raji, Daudi, Nalm6) leukaemic cell lines obtained from the ATCC (American Type Culture Collection, Rockville, USA) or the DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany). The adenovirus 5 Tantigen-transformed human embryonal kidney cell line 293 (kindly provided by N Barron, Manchester, UK) and the gastric adenocarcinoma cell line Kato III (kindly provided by SA Hahn, Bochum, Germany) served as positive and negative controls for FHIT protein analysis, respectively. Cell lines were cultured either in McCoy's medium (Gibco BRL, Grand Island, USA) or in RPMI 1640 (Life Technologies, Paisley, Scotland, UK) supplemented with 10 ± 15% fetal bovine serum (Nabi, Miami, USA) in a humi®ed atmosphere containing 5% CO 2 at 378C.
We investigated samples from 55 patients with haematological malignancies including 21 acute myeloid leukaemias (AML), eight chronic myeloid leukaemias (CML), 10 chronic lymphocytic leukaemias (CLL), as well as seven low-grade (Lg-NHL) and nine high-grade B-cell Non-Hodgkin's lymphomas (Hg-NHL) diagnosed according to the REALclassi®cation. Mononuclear cells from untreated leukaemias containing 490% malignant cells as assessed by morphology were enriched by Ficoll density gradient centrifugation (Histopaque 1.077 g/L; Sigma, St Louis, USA). All lymphoma biopsies were snapfrozen and stored at 7708C until use.
RNA extraction, RT ± PCR and sequencing
From all samples total cellular RNA was extracted using either RNAzolB 1 (Tel-Test Inc., Friendswood, USA) or RNeasy 1 (Qiagen, Hilden, Germany). Random-primed ®rst-strand cDNA was synthesized from total RNA (0.5 ± 1 mg/20 ml reaction) using the 1st Strand cDNA Synthesis Kit 1 (Boehringer, Mannheim, Germany). The entire coding region of the FHIT gene was ampli®ed using a sensitive nested touchdown RT ± PCR. 5 ± 10 ml of cDNA were subjected to a ®rst PCR round using primers 5U2 and 1038R according to GenBank accession number U46922 Ohta et al., 1996) . After an initial denaturation step at 948C for 5 min primer annealing started at 708C, and subsequently the annealing temperature was decreased by 18C per cycle for the ®rst ®ve cycles until the de®nitive annealing temperature of 658C used for the following 25 cycles was reached. The other PCR conditions remained constant throughout including denaturation at 948C for 15 s, and primer extension at 728C for 45 s. Reactions were carried out in a volume of 30 ml with 10% glycerol under standard conditions using Taq DNA polymerase (Boehringer, Mannheim, Germany) on a DNA Thermal Cycler 9600 (Perkin Elmer, Foster City, USA). After a 20-fold dilution 1 ml of the reaction product was ampli®ed in a nested PCR reaction with primers 203F and 904R for another 30 cycles to increase the sensitivity . Since this highly sensitive nested PCR might favour the ampli®cation of small aberrant FHIT mRNA transcripts, selected samples were reanalysed using a single step touchdown PCR with primers 203F and 904R for 40 cycles under the conditions described above. No dierences in the band patterns of ampli®cation products were noted. RNA integrity was veri®ed by RT ± PCR ampli®cation of b-actin RNA (Schwaller et al., 1997) . All PCR products were separated on 1.5% agarose gels and stained with ethidium bromide. Bands of interest visible on agarose gels were sequenced directly after excision and spin columnpuri®cation (Qiagen, Hilden, Germany). Other bands including those visible only on autoradiographs after hybridization were analysed through cloning of 1 ml of PCR product into a pCR-TOPO vector (Invitrogen, NV Leek, The Netherlands) and subsequent screening of the colonies. Sequencing was performed with primers 203F and 904R using the Dye terminator DNA cycle sequencing kit and sequencer 373A (Applied Biosystems, Foster City, USA). Sequencing data were analysed with the Wisconsin Package Version 9.0 (Genetics Computer Group, Madison, USA).
Southern blot hybridization of PCR products
RT ± PCR products were electrophoresed on 1.5% agarose gels, Southern blotted and hybridized with a PCRgenerated digoxigenin-labeled cDNA probe containing exons 1 ± 10 (positions 140 ± 1038) of the FHIT gene. The signals were detected with chemiluminescent alkaline phosphatase substrate (Boehringer, Mannheim, Germany) after exposure to X-ray ®lms. In order to rule out nonspeci®c hybridization of the cDNA probe PCR products which were unrelated to the FHIT gene were co-blotted on the ®lters and thus served as negative controls. As a positive control a sequenced PCR amplicon from the normal FHIT gene was included.
Analysis of genomic DNA by Southern blotting
Five mg of genomic DNA from malignant and normal cells was digested with the restriction enzymes BamHl, HindIII and XbaI (Boehringer, Mannheim, Germany) selected according to published restriction data . The fragments which included the entire gene were size-fractioned in 0.7% agarose gels and Southern blotted. The PCR-generated cDNA probe spanning FHIT exons 1 ± 10 was [a 32 P]dCTP by random priming (Boehringer, Mannheim, Germany). Filters were hybridized, washed under stringent conditions and autoradiographed. Equal DNA loading was veri®ed by cross-hybridization with a DNA probe recognizing the 5'bcr region on chromosome 22 (Groen et al., 1984) .
Immunoprecipitation and Western blot analysis
For immunoprecipitation, 10 ± 20610 6 cells were lysed in ice-cold NP40 buer containing 150 mM NaCl, 50 mM Tris-HCL (pH 8.0), 0.5% NP40 and complete protease inhibitors (Boehringer, Mannheim, Germany). The lysates were then centrifuged to remove debris. 1 ± 2 mg of total protein was incubated with 2 ml of a polyclonal rabbit anti-FHIT IgG antiserum (kindly provided by Dr K Huebner, Philadelphia, USA) (Barnes et al., 1996) on a rotator at 48C for 2 h. Immune complexes were collected on 35 ml protein A-Sepharose (Pharmacia Biotech AB, Uppsala, Sweden) after incubation for 1 h and were washed three times in 0.5 ml ice-cold NP40 buer. The beads were resuspended in 35 ml of 26sample buer. For Western blot analysis 5 ± 10610 6 cells were lysed in electrophoresis sample buer (80 mmol/L Tris-HCl [pH 6.8], 2% SDS, 2% 2-Mercaptoethanol, 10% glycerol). Both immunoprecipitated and total protein samples were boiled for 5 min, subjected to electrophoresis in 12% SDS-polyacrylamide and transferred to nitrocellulose ®lters. The membranes were blocked with 2.5% dried milk in TBST for 1 h, washed three times with TBST and incubated overnight with the FHIT antibody (1 : 3000 dilution in TBST). After three ®nal TBST washes the FHIT protein was detected with a peroxidase-labeled anti-rabbit antibody (1 : 2000 dilution in TBST) using the ECL system (Amersham, ZuÈ rich, Switzerland).
